XORTX Therapeutics Files 6-K with Q2 2024 Financials
Ticker: XRTX · Form: 6-K · Filed: Aug 15, 2024 · CIK: 1729214
Sentiment: neutral
Topics: financials, reporting, biotech
TL;DR
XORTX dropped Q2 financials on 8/15. Check the statements and MD&A.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on August 15, 2024, reporting its financial results for the period ending June 30, 2024. The filing includes condensed interim consolidated financial statements and management's discussion and analysis. Allen Davidoff, CEO, signed the report on August 14, 2024.
Why It Matters
This filing provides investors with an update on XORTX Therapeutics' financial performance and operational status for the second quarter of 2024, crucial for assessing the company's health and future prospects.
Risk Assessment
Risk Level: medium — As a clinical-stage biotechnology company, XORTX faces inherent risks related to drug development, regulatory approvals, and market adoption.
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- Allen Davidoff (person) — Chief Executive Officer
- August 14, 2024 (date) — Signature date
- June 30, 2024 (date) — Reporting period end date
FAQ
What specific financial statements are included in this 6-K filing?
The filing includes Exhibit 99.1, which contains the Condensed Interim Consolidated Financial Statements for the three months ended June 30, 2024.
Who signed the Form 6-K on behalf of XORTX Therapeutics Inc.?
The Form 6-K was signed by Allen Davidoff, Chief Executive Officer, on August 14, 2024.
What is the fiscal year end for XORTX Therapeutics Inc.?
The fiscal year end for XORTX Therapeutics Inc. is December 31.
What is the Commission File Number for XORTX Therapeutics Inc.?
The Commission File Number for XORTX Therapeutics Inc. is 001-40858.
What other documents are attached as exhibits to this 6-K filing?
In addition to the financial statements (Exhibit 99.1), the filing includes Management Discussion and Analysis (Exhibit 99.2), CEO Certificate (Exhibit 99.3), and CFO Certificate (Exhibit 99.4).
Filing Stats: 161 words · 1 min read · ~1 pages · Grade level 10 · Accepted 2024-08-14 20:35:57
Filing Documents
- f6k_081424.htm (6-K) — 7KB
- exh_991.htm (EX-99.1) — 376KB
- exh_992.htm (EX-99.2) — 237KB
- exh_993.htm (EX-99.3) — 9KB
- exh_994.htm (EX-99.4) — 9KB
- logo.jpg (GRAPHIC) — 35KB
- 0001171843-24-004808.txt ( ) — 688KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-40858 XORTX Therapeutics Inc. 3710 – 33 rd Street NW, Calgary, Alberta, T2L 2M1 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XORTX THERAPEUTICS INC. (Registrant) Date: August 14, 2024 By: /s/ Allen Davidoff Name: Allen Davidoff Title: Chief Executive Officer EXHIBIT INDEX 99.1 Condensed Interim Consolidated Financial Statements for the three months ended June 30, 2024 99.2 Management Discussion and Analysis for the three months ended June 30, 2024 99.3 CEO Certificate 99.4 CFO Certificate